Merletti (AstraZeneca): ‘We invest to be a leader in oncohematology’

“Astrazeneca has a strong commitment to clinical research in oncohematology that derives from an important portfolio that is destined to grow: we are talking about more than 50 therapeutic solutions that will reach patients by 2025. Currently in Italy there are more than 80 clinical trials between phase 1 phase 2 and phase 3, including studies in the early stages of the disease therefore with potential curative intent. In addition, we have over 20 studies in haematological diseases, we are investing a lot to become a leader in hematology “. Thus Mirko Merletti, Vice President Oncology AstraZeneca, speaking this morning on the sidelines of the event “Cancer: the new frontiers of treatments in oncology and hematology” promoted and organized by AstraZeneca at the ‘La Nuvola’ Congress Center in Rome. “AstraZeneca’s commitment – underlines Merletti – is in early diagnosis because we want to increase the chance of patient care, thanks to molecules studied in early settings. We are also committed to early diagnosis with screening to accelerate access to innovative therapies and improve patient care pathways. ”“ We are experiencing a revolution that Astrazeneca is leading together with the scientific community. Only in the coming months and years will we have the confirmation of what we are doing, the possibility of being able to arrive with innovative therapeutic solutions for patients ”he concludes.